Business
Telix, United Imaging explore U.S. theranostics research
Telix and United Imaging Healthcare North America will evaluate a U.S. research collaboration focused on scanner, software, AI, and radiopharmaceutical workflow integration.
Company
Telix Pharmaceuticals
Australian biopharmaceutical company headquartered in Melbourne, focused on developing and commercializing diagnostic and therapeutic radiopharmaceuticals (theranostics) for oncology and rare diseases. Telix is listed on the Australian Securities Exchange and Nasdaq under the ticker TLX.
Business
PSMA PET guidance anchors EDAP-Telix HIFU prostate work
EDAP TMS and Telix Pharmaceuticals signed a letter of intent to explore clinical research combining Focal One Robotic HIFU with Telix PSMA PET imaging agents in prostate cancer care.
Clinical
Telix phase 3 trial tests radiopharmaceutical therapy for recurrent glioblastoma
The IPAX BrIGHT trial is evaluating TLX101-Tx with lomustine versus lomustine alone in patients with recurrent glioblastoma.
Business
Telix and Regeneron target solid tumors in $2.1B radiopharma pact
The companies will co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Telix receiving $40M upfront and eligibility for up to $2.1B in milestones.
Business
Regeneron taps Telix platform for solid-tumor radiopharma programs
The companies will co-develop radiopharmaceutical therapies and radiodiagnostics across multiple solid tumor targets.
Clinical
Telix glioma PET agent moves toward FDA decision
The FDA assigned a September 11, 2026, PDUFA goal date for Pixclara, an investigational F-18 FET PET agent for glioma imaging.